141 related articles for article (PubMed ID: 26305037)
1. Haematological cancer: Resiquimod—a topical CTCL therapy.
Killock D
Nat Rev Clin Oncol; 2015 Oct; 12(10):563. PubMed ID: 26305037
[No Abstract] [Full Text] [Related]
2. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.
Rook AH; Gelfand JM; Wysocka M; Troxel AB; Benoit B; Surber C; Elenitsas R; Buchanan MA; Leahy DS; Watanabe R; Kirsch IR; Kim EJ; Clark RA
Blood; 2015 Sep; 126(12):1452-61. PubMed ID: 26228486
[TBL] [Abstract][Full Text] [Related]
3. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Whitmore SE
J Am Acad Dermatol; 2004 Sep; 51(3):482; author reply 482-3. PubMed ID: 15338005
[No Abstract] [Full Text] [Related]
4. Bexarotene monotherapy for epidermotropic CD8+ CTCL.
Kamstrup M; Gniadecki R
Dermatol Clin; 2008 Jan; 26 Suppl 1():45-7. PubMed ID: 18405187
[No Abstract] [Full Text] [Related]
5. Future directions for pentostatin (Nipent) usage in dermatology.
Heald P
Semin Oncol; 2000 Apr; 27(2 Suppl 5):3-8. PubMed ID: 10877044
[TBL] [Abstract][Full Text] [Related]
6. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development.
Mirza FN; Yumeen S; Lewis JM; King ALO; Kim SR; Carlson KR; Umlauf S; Surovtseva YV; Foss FM; Girardi M
J Invest Dermatol; 2021 Jan; 141(1):217-221. PubMed ID: 32534802
[No Abstract] [Full Text] [Related]
7. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
8. New drugs in cutaneous T-cell lymphomas.
Scarisbrick JJ
Curr Opin Oncol; 2016 Sep; 28(5):384-9. PubMed ID: 27390044
[TBL] [Abstract][Full Text] [Related]
9. Topical treatment of early cutaneous T-cell lymphoma.
Ramsay DL; Meller JA; Zackheim HS
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1031-56. PubMed ID: 8522483
[TBL] [Abstract][Full Text] [Related]
10. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
11. Denileukin diftitox.
Saxon M
Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
[TBL] [Abstract][Full Text] [Related]
12. [Interferon alpha in the treatment of cutaneous T-cell lymphoma].
Dréno B
Ann Dermatol Venereol; 2005 Sep; 132 Spec No 2():5S27-30. PubMed ID: 16385896
[No Abstract] [Full Text] [Related]
13. Therapeutic Update: Update on Cutaneous and Systemic Therapy for Primary Cutaneous T Cell Lymphoma, Mycosis Fungoides.
Lo Sicco K; Latkowski JA
J Drugs Dermatol; 2015 Dec; 14(12):1381-3. PubMed ID: 26659928
[No Abstract] [Full Text] [Related]
14. Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma.
Chung CG; Poligone B
Dermatol Clin; 2015 Oct; 33(4):787-805. PubMed ID: 26433850
[TBL] [Abstract][Full Text] [Related]
15. The role for interleukin-12 therapy of cutaneous T cell lymphoma.
Rook AH; Zaki MH; Wysocka M; Wood GS; Duvic M; Showe LC; Foss F; Shapiro M; Kuzel TM; Olsen EA; Vonderheid EC; Laliberte R; Sherman ML
Ann N Y Acad Sci; 2001 Sep; 941():177-84. PubMed ID: 11594571
[TBL] [Abstract][Full Text] [Related]
16. New skin cancer drug.
FDA Consum; 2007; 41(1):2. PubMed ID: 17342825
[No Abstract] [Full Text] [Related]
17. Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma.
Besner Morin C; Roberge D; Turchin I; Petrogiannis-Haliotis T; Popradi G; Pehr K
J Cutan Med Surg; 2016 May; 20(3):244-8. PubMed ID: 26742957
[TBL] [Abstract][Full Text] [Related]
18. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod.
Stavrakoglou A; Brown VL; Coutts I
Br J Dermatol; 2007 Sep; 157(3):620-2. PubMed ID: 17553050
[No Abstract] [Full Text] [Related]
20. Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas.
Urosevic M
Curr Opin Investig Drugs; 2007 Jun; 8(6):493-8. PubMed ID: 17621880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
